|Bid||3.2400 x 3100|
|Ask||3.2700 x 4000|
|Day's Range||3.1600 - 3.3850|
|52 Week Range||0.7800 - 5.9800|
|Beta (5Y Monthly)||2.29|
|PE Ratio (TTM)||N/A|
|Earnings Date||Jul 28, 2021 - Aug 02, 2021|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||8.50|
CAMBRIDGE, Mass., Jun 14, 2021--Infinity Pharmaceuticals, Inc. (NASDAQ: INFI), a clinical-stage biotechnology company developing eganelisib, a potentially first-in-class, oral, immuno-oncology macrophage reprogramming therapeutic which addresses a fundamental biologic mechanism of immune suppression in cancer, today announced that Dr. Brian Schwartz will present a summary of recent eganelisib clinical data followed by a Q&A session at the Keystone Symposia Precision Oncology: Translating Discove
Performance at Infinity Pharmaceuticals, Inc. ( NASDAQ:INFI ) has been reasonably good and CEO Adelene Perkins has done...
We can readily understand why investors are attracted to unprofitable companies. By way of example, Infinity...